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Background: Women who use drugs are extremely vulnerable to HIV and sexually transmitted infections (STIs), but
studies on risk behaviours and HIV infection among female drug users are limited in Nepal.
Methods: In this cross-sectional study conducted between September 2010 and May 2011, HIV prevalence and risk
factors for HIV infection were investigated among female drug users recruited in drop-in centres, parks and streets
in the Kathmandu Valley. The participants completed face-to-face interviews for a structured questionnaire, HIV
pre-test counselling, specimen collection for HIV test and they were provided with their results at post-test
counselling.
Results: A total of 269 female drug users were recruited, of whom 28% (n = 77) were found HIV positive; the
majority (78%, n = 211) being injecting drug users and aged below 25 years (57%, n = 155). Nearly half (n = 137) of
the total participants had shared needles or syringes in the past month, and 131 and 102 participants were
involved in commercial or casual sex respectively with only half or less of them having had used condoms in the
last 12 months. In multivariate analysis the variables associated with HIV infection included: (a) older age; (b) history
of school attendance; (c) frequency of sharing of injection instruments; and (d) unsafe sex with commercial or
casual partners.
Conclusions: HIV was highly prevalent among female drug users in the Kathmandu Valley, with its risk being
strongly associated not only with unsafe injection practice but also with unsafe sexual behaviours. Awareness
raising programmes and preventive measures such as condom distribution, needle or syringe exchange or
methadone maintenance therapy should be urgently introduced in this neglected subpopulation.
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The World Drug Report 2013 estimated that in 2011 bet-
ween 167 to 315 million people aged 15–64 (3.6% - 6.9%
of the world’s population in that age group) had used an
illicit substance at least once in the previous year [1]. In
the same report, the United Nations Office on Drugs and
Crime (UNODC) estimated that about 14 million people
inject drugs globally and of them 1.6 million (11.4%) are
living with HIV. Countries with higher prevalence of HIV
infection among people who inject drugs are located in* Correspondence: p.bhagabati@gmail.com
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reproduction in any medium, provided the orWestern and Central Europe, Sub-Saharan Africa, and
South and South-East Asia including Nepal [2]. In recent
years, there has been a rapid increase in female injecting
drug users, especially in Asia and Eastern Europe [3,4]. In
Central Asia and the countries like China, India and
Russia, drug use and sharing injection equipment is in-
creasing rapidly among females, and in many regions
more females are seeking harm reduction services and
drug treatment [5,6].
In Nepal, the first case of HIV/AIDS was reported in
1988. As of 2011, national estimates indicated that ap-
proximately 50,200 adults and children were infected
with HIV, with an estimated overall HIV prevalence of
0.30% in the adult population of 15 to 49 years. Out ofl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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occurred among females [7]. Although estimated HIV
prevalence among Nepal’s adult population is fairly low, the
HIV epidemic in Nepal is extremely heterogeneous with
respect to the most at risk populations and geographic dis-
tribution [8,9]. The epidemic is concentrated in key sub-
populations such as commercial sex workers, injecting drug
users (IDUs), men who have sex with men, and migrants.
IDUs are the subpopulation most heavily affected by the
epidemic [10,11]. The drug user population is concentrated
in the Kathmandu Valley and in the locations along the
East–west Highway, where 30% of all the people living with
HIV are IDUs. According to a government report, 42,954
(92.8%) male and 3,356 (7.2%) female drug users were living
in the Kathmandu Valley alone in 2007 where 34.8% of
IDUs were estimated to be HIV positive [12,13].
Compared to male drug users, information has been
limited for female drug users regarding HIV prevalence
and their risk behaviours. Though smaller in number, the
situation of female drug users could be more serious than
that of male drug users for several reasons. Firstly, female
drug users are known to trade sex for money or drugs. A
study has shown that over half of the female IDUs in
China have been involved in sex work [14]. Secondly,
female drug users who exchange sex for drugs or cash
may not identify themselves at risk of HIV infection be-
cause they do not consider themselves as sex workers
[15]. Thirdly, condom use can be infrequent among them
because drug dependency and financial problems may im-
pair their judgment and power to negotiate for condom
use with their sex partners [16-19]. Fourthly, female drug
users depend in many cases on male partners for drugs
and injections, leading them to an elevated risk of equip-
ment sharing practice [20,21]. Fifthly, female drug users
are socially stigmatized more than male drug users, ma-
king them hidden and thus it is difficult for them to access
preventive services [21-23]. For these reasons, female drug
users could expose themselves to exceptional risk of HIV
infection and play a critical role in the local HIV epidemic
by bridging infection to the broader population through
their drug injection network as well as sexual network
[18,24,25]. These situations, however, largely remain un-
known in Nepal.
With these backgrounds, this study aims to investigate
prevalence of HIV infection and social and behavioural
correlates of HIV infection among female drug users in
Kathmandu Valley, Nepal, with a hope that it may help to
improve intervention programmes for female drug users
in Nepal.
Methods
Setting and sampling procedures
This cross-sectional study was conducted between
September 2010 and May 2011 among female drug usersof Kathmandu Valley, in which the capital city is situated.
Female drug users were recruited in drop-in centres
(DICs) that were working for various drug-related harm
reduction programmes for female drug users as well as in
parks and on the street. Recruitment was carried out
directly by ex-drug users and trained outreach workers
and indirectly through personal networks. The outreach
workers first mapped out the groups and areas where they
expect to encounter the target population, and they then
set out to actively recruit potential candidates there. The
time of field observations varied to cover morning, after-
noon, evening, and late night hours. They often made use
of existing social networks within a population. As selec-
tion proceeds, suitable new candidates with appropriate
characteristics or behaviour were sought within the social
networks of respondents already included in the study
(snowball sampling) [26]. The inclusion criteria for the
study was that they were current drug users of at least
16 years old and willing to give informed consent for both
questionnaire survey and HIV testing. Eligible respon-
dents received an explanation about the survey, its pur-
pose and types of the questions to be asked.
Interview
Trained outreach workers and peer educators of the HIV/
AIDS programme who had already established trust with
female drug users through their daily activities interviewed
participants face to face using structured questionnaires.
A small incentive was provided to each participant for
travel and refreshment. The name of the participants or
their addresses were not recorded anywhere. Instead, they
were provided with a unique identification (ID) number
written on a plastic-coated card that was used for both
questionnaire and HIV testing. Same ID was used for pre-
and post-counselling and for the provision of test results.
Instrument
The structured questionnaire was developed from a ques-
tionnaire recommended and produced by Family Health
International for IDUs [27]. With modifications made fol-
lowing the findings of the preliminary qualitative study
(conducted among 21 female drug users in May 2010), the
final questionnaire included 90 questions. The topics in
the questionnaire included the main socio-demographic
characteristics, drug use practices, frequency and duration
of injection drug use, sexual activities and a history of
sexually transmitted infections (STIs), and knowledge and
perception of HIV/AIDS. Questions on knowledge in-
cluded: (1) Can people protect themselves from HIV by
using condoms?; (2) Can a person get HIV from mosquito
bites?; (3) Can people protect themselves from HIV by
having one uninfected faithful sex partner?; (4) Can people
protect themselves from HIV by abstaining from sexual
intercourse?; (5) Can a person get HIV by sharing a meal
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through injections with a needle that was already used by
someone else?; (7) Can people who inject drugs protect
themselves from HIV by switching to non-injecting
drugs?; (8) Can a pregnant woman infected with HIV
transmit the virus to her unborn child?; and (9) Can a
woman with HIV transmit the virus to her newborn child
through breastfeeding? All of these questions were given
in a Likert scale with options of “yes”, “no” and “do not
know”.
HIV testing
After completing the interview, blood samples were col-
lected from each study participant by finger prick blood
sampler complying with the National HIV Testing Pro-
tocol. Considering the availability of limited human and
financial resources, the Ministry of Health and Population
of Nepal has recommended the use of two or more rapid
tests based on different test principles (antigens) as a mi-
nimum standard HIV test algorithm to be followed at all
levels of the health care delivery system [28]. Two rapid
test kits Determine HIV 1/2 and Uni-Gold HIV 1/2 were
used for the purpose. The initial screening test was per-
formed using Determine HIV 1/2 and then retested using
the Uni-Gold HIV 1/2 when the first test result was posi-
tive for confirmation. A third test SD Bioline HIV 1/2 was
performed for final confirmation when there was discre-
pancy in the first two tests. If the third test showed a
reactive result, the tested sample was reported as “HIV
positive” and if the third test showed a non-reactive result,
it was reported as “HIV negative”. Sensitivity and specifi-
city of combined testing algorism of Determine and SD
Bioline are reported to be both 100% [29,30]. The HIV test
results were kept confidential. Pre-test counselling was
provided as a part of informed consent and the partici-
pants were informed of the testing result only at post-test
counselling.
Ethical issues
This research protocol was approved by the Nepal Health
Research Council and the Committee for Research on
Human Subjects at Kyoto University in Japan. Separate
written informed consents were obtained for the interview
and HIV testing, and no personal identifier was recorded
on the questionnaires. All the participants were advised to
undertake free HIV testing for final clinical diagnosis.
Statistical analysis
Statistical analyses were carried out using SPSS software
for Windows (version 19, IBM Inc., Chicago). Bivariate
analyses were conducted to estimate the association of
demographic or behavioural variables with HIV infec-
tion, calculating crude odds ratio (OR) with 95% confi-
dence interval (CI). Multiple multivariate models wererun: (a) to compare the predictive powers of behavioural
variables of different time frames; and (b) to show in-
dependent correlates to HIV infection. The significant
variables from bivariate analyses, epidemiologically im-
portant variables and synthetic variables created by com-
bining related variables were included in the models.
Independent variables were assessed for multicollinearity,
variance inflation factor and tolerance statistics were
within acceptable limits for all variables [31]. From multi-
variate models adjusted odds ratio (AOR) and 95% CI
were calculated. A p-value less than 0.05 (2-sided) was
considered to be statistically significant. Answers to the
HIV knowledge questions were transformed into scores
by giving 1 for correct answer and 0 for otherwise.
Results
A total of 269 participants were included in the analysis,
of whom 28.6% were HIV positive. The major socio-
demographic characteristics of the participants are shown
in Table 1.
More than half (52.0%) of the study participants were
recruited in the streets. No association was detected bet-
ween sites of recruitment and HIV status of the partici-
pants (p = 0.98). More than half of the participants (57.6%)
were under 25 years old; the median age being 23 years.
HIV infection was found to be associated with older age
groups; the prevalence being 50.0% in the 30 years and
above. The majority (76.2%) of the participants were
married and/or cohabitating with their sexual partners,
which is highly associated with HIV infection (p = 0.002 or
p < 0.001). More than 80% of the participants had ever
been to school, and the HIV prevalence (34.1%) is much
higher in this group than those without school education
(4.1%) (p = 0.001). Although 53.3% of the participants
were unemployed, the job situation of the participants was
unrelated to the HIV status (p = 0.307).
Table 2 shows the prevalence of risky behaviours in this
population and the results of bivariate analyses between
HIV status and HIV/STI knowledge score or behavioural
variables. Risky behaviours are highly prevalent in this
population. Injection practice in lifetime was reported
from 78.4% (211/269); of them 24.2% (51/211) shared
needles and/or syringes most times or always, and 86.7%
(183/211) had shared a cooker or other utensils some-
times or more with other people in the past one month.
Sex with regular, non-regular non-commercial partners
(herein after “casual partners”) and commercial partners
were reported by 74.1% (166/224), 45.5% (102/224) and
58.5% (131/224) of sexually active participants respec-
tively. Among them 79.5% (132/166), 75.5% (77/102) and
87.8% (115/131) reported that they are not always using
condoms, respectively.
All these variables are significantly associated with in-
creased risk of HIV infection except for HIV knowledge.











Street/Park 40 (28.6) 140 1.00
Drop in centre 37 (28.7) 129 1.01 (0.59-1.71) 0.984
Age (years)
16 - 19 7 (25.9) 27 1.00
20 - 24 25 (19.5) 128 0.69 (0.26-1.82) 0.457
25 - 29 28 (35.0) 80 1.54 (0.58-4.08) 0.387
30 - 38 17 (50.0) 34 2.86 (0.96-8.52) 0.060
Mean (SD) (Median) 26.3 (6.0) (25.0) 24.4 (4.8) (23.0) 1.12 (1.06-1.18) <0.001
Marriage and live-in partnerships
Not married, not living with sexual partner 6 (9.4) 64 1.00
Not married, living with sexual partner 25 (32.5) 77 4.65 (1.77-12.22) 0.002
Currently married, not living with spouse or any other sexual partner 12 (36.4) 33 5.52 (1.84-16.59) 0.002
Currently married, living with spouse or other sexual partner 34 (35.8) 95 5.39 (2.11-13.79) <0.001
Level of education
Never went to school 2 (4.1) 49 1.00
Primary (1–5 years) 15 (48.4) 31 22.03 (4.54-107.04) <0.001
Secondary (6–10 years) 26 (27.4) 95 8.86 (2.01-39.10) 0.004
Higher (11 years and higher) 34 (36.2) 94 13.32 (3.04-58.28) 0.001
Job situation
Have a job 32 (25.6) 125 1.00
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injected (OR = 3.04, p = 0.006) as well as among those
who ever used needle or syringes previously used by
someone else (OR = 3.08, p < 0.001). Frequency of injec-
tion in the past one month is associated with positive HIV
status in a dose-dependent manner; the participants
injecting once or more a day have the highest (39.2%) HIV
prevalence (OR = 4.03, p = 0.001). Frequency of sharing
injection instruments or other accessory utensils such as a
cooker in the past one month is also associated with
positive HIV status but not in a dose-dependent manner.
Sexual experiences, both over a life time and in the last
12 months, are strongly associated with HIV status with
equivalent magnitudes (OR = 10.82 and 9.13, p ≤ 0.001).
Similarly, sexual experience with any type of partner in
the past 12 months is strongly associated with the HIV
status (OR = 3.50-5.91, p < 0.001) with the highest asso-
ciation being with casual partners. The majority of the
participants used condoms inconsistently with any type of
sexual partner. The frequency of condom use with aregular partner or casual partner is associated with HIV
status in a dose-dependent manner. The prevalence is
highest among the participants who never or only some-
times used condoms with their regular partners (40.4%,
OR = 3.97, p < 0.001) or casual partner (55.2%, OR = 6.99,
p < 0.001). The frequency of condom use with commercial
partners is also significantly associated with the HIV status
but not in a dose-dependent manner.
Table 3 summarizes the results of multivariate analyses
of factors associated with HIV infection. Multiple logis-
tic regression analyses were carried out using beha-
vioural variables with different time frames as well as
synthetic variables with different risk specificities. This
analytic strategy was adopted because although some
questions were asked in an “ever” time frame for injec-
tion and sexual behaviours, the rest of the questions
were asked in different time frames; “in the past one
month” for drug use and “in the past 12 months” for
sexual behaviours. It seemed therefore necessary to as-
sess the effect of the time frame on the predictive power











6 - 9 66 (27.8) 237 1.00
0 - 5 11 (34.4) 32 1.36 (0.62-2.97) 0.445
Drug use behaviour
Ever injected illegal/non-medical drugs
No 8 (13.8) 58 1.00
Yes 69 (32.7) 211 3.04 (1.37-6.76) 0.006
Ever used a needle or syringe previously used by someone else
No/Non-IDU 23 (17.4) 132 1.00
Yes 54 (39.4) 137 3.08 (1.75-5.43) <0.001
Frequency of injecting with a needle or syringe previously used by someone
else in the past one month
Non-IDU/Never 24 (17.5) 137 1.00
Occasionally/About half the time 36 (44.4) 81 3.77 (2.02-7.01) <0.001
Always/Most times 17 (33.3) 51 2.35 (1.13-4.89) 0.022
Frequency of sharing cooker/vial/container, cotton/filter, or rinse water when
injecting in the past one month
Never/Non-IDU 19 (22.1) 86 1.00
Sometimes 17 (21.8) 78 0.98 (0.47-2.06) 0.963
Always/Often 41 (39.0) 105 2.26 (1.19-4.30) 0.013
Frequency of injecting drugs in the past one month
Non-IDU 8 (13.8) 58 1.00
6 times a week or LESS 9 (15.5) 58 1.15 (0.41-3.22) 0.793
1 time a day or MORE 60 (39.2) 153 4.03 (1.79-9.10) 0.001
Sexual behaviour
Ever had sexual intercourse
No 2 (4.4) 45 1.00
Yes 75 (33.5) 224 10.82 (2.55-45.89) 0.001
Sexual intercourse in the last 12 months with any type of partner
No/Never had sex 4 (5.9) 68 1.00
Yes 73 (36.3) 201 9.13 (3.19-26.08) <0.001
Sexual intercourse with regular partner in the last 12 months
No/Never had sex 15 (14.6) 103 1.00
Yes 62 (37.3) 166 3.50 (1.86-6.58) <0.001
Sexual intercourse with commercial partner in the last 12 months
No/Never had sex 19 (13.8) 138 1.00
Yes 58 (44.3) 131 4.98 (2.75-9.02) <0.001
Sexual intercourse with non-regular non-commercial partner in the last 12 months
No/Never had sex 25 (15.0) 167 1.00
Yes 52 (51.0) 102 5.91 (3.32-10.51) <0.001
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Table 2 Bivariate association of behavioural factors with HIV infection among female drug users recruited in the
Kathmandu Valley, Nepal (Continued)
Frequency of condom use in the last 12 months with all regular partners
Never had sex/No sex with regular partner in the last 12 months 15 (14.6) 103 1.00
Always/Often 20 (32.3) 62 2.79 (1.30-6.00) 0.008
Sometimes/Never 42 (40.4) 104 3.97 (2.03-7.79) <0.001
Frequency of condom use in the last 12 months with all commercial partners
Never had sex/No sex with commercial partner in the last 12 months 19 (13.8) 138 1.00
Always/Often 36 (54.5) 66 7.52 (3.79-14.91) <0.001
Sometimes/Never 22 (33.8) 65 3.20 (1.58-6.49) 0.001
Frequency of condom use in the last 12 months with all non-regular
non-commercial partners
Never had sex/No sex with casual partner in the last 12 months 25 (15.0) 167 1.00
Always/Often 20 (45.5) 44 4.73 (2.28-9.82) <0.001
Sometimes/Never 32 (55.2) 58 6.99 (3.58-13.66) <0.001
Non-IDU, non-injecting drug user.
OR, odds ratio.
CI, confidence interval.
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power of the variables would be enhanced by creating
synthetic variables to represent more directly the risk of
behaviours.
Models 1 to 6 include all drug users but model 7 in-
cludes only injecting drug users. “Ever injected illegal/
non-medical drugs” and “Ever had sexual intercourse”
were entered in model 1, while the latter was replaced
with “Had sexual intercourse in the last 12 months” in
model 2 showing that association of sexual behaviour is
more prominent “in the last 12 months” than “ever”. In
models 3 and 4, on the other hand, a variable “Ever
injected illegal/non-medical drugs” was replaced with a
variable “Ever used needles or syringes previously used by
someone else” (model 3) or a synthetic variable “Used
needles or syringes previously used by someone else
in the past one month” (model 4), while keeping the
variable “Ever had sexual intercourse” the same as in
model 1. From the comparison of models 1 to 4, it
was shown that all injection variables had equivalent
predictive power (AOR = 2.5) irrespective of time frame or
the presence/absence of sharing practice, and that sexual
variables had predictive powers that were equivalent
to or more potent than the injection variables among
the participants.
Model 5 is an extension of model 2 where the risks of
sexual intercourses with different types of partners in
the past 12 months with HIV infection were compared.
While significant association was detected for sexual in-
tercourses with commercial and casual partners, it was
not significant with regular partners. Model 6 is the
extension of model 4 using a synthetic variable where
“Used needles or syringes previously used by someoneelse in the past one month” was combined with the fre-
quency of injection in the past month. It was shown that
frequent unsafe injection practice (sharing needles and
syringes once a day or more) and frequent unsafe sex
(intercourses with ‘sometimes or never’ condom use) with
casual partners were significantly associated with HIV in-
fection, while with commercial sexual partners inter-
courses with ‘always or often’ rather than infrequent
condom use showed significant association. Such an
association pattern was maintained when analysis was con-
fined to female injecting drug users (model 7). Throughout
these models, age and “Ever attended school” but not
“Marital status” were significantly associated with HIV in-
fection. “Ever attended school” was the most potent pre-
dictor of HIV infection, while its association nearly halved
when sexual behaviour variables were switched from the
general ones to those specific to sexual partners. Beha-
vioural and injecting practice variables were introduced in
the order of all possible combinations into models 5
through 7, yielding similar results.
Discussion
Overall, HIV prevalence in this population was revealed
to be 28.6%; 33% in those who practised injecting drug
use and 14% even among those who reportedly never ex-
perienced injecting drug use. In Nepal, the Integrated
Biological and Behavioral Surveillance (IBBS) surveys are
conducted at regular intervals among male IDUs. The
latest round of IBBS showed a significant decline in HIV
prevalence among male IDUs in Kathmandu Valley, from
51.7% in 2005 to 6.3% in 2009 [10], which is much lower
than the HIV prevalence we found among female IDUs.
This study strongly suggests that female drug users are
Table 3 Multivariate association of behavioural factors with HIV infection among female drug users in the Kathmandu
Valley, Nepal
All drug users Only IDUs
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Adjusted odds ratio
(95% confidence interval)
Age 1.10* 1.10* 1.11* 1.11* 1.07* 1.07 1.08*
(1.04-1.17) (1.03-1.17) (1.04-1.18) (1.04-1.19) (1.01-1.15) (1.00-1.15) (1.00-1.17)
Ever attended school (ref. No) 10.85* 9.03* 10.83* 10.52* 6.14* 6.21* 4.85
(2.46-47.79) (2.05-39.73) (2.44-48.13) (2.38-46.56) (1.34-28.06) (1.31-29.49) (0.96-24.55)
Currently married, or currently not married but
living with sex partner (ref. Not married,
not living with sexual partner)
2.33 2.15 1.84 1.85 2.01 1.62 1.69
(0.72-7.53) (0.78-5.94) (0.57-5.96) (0.57-6.01) (0.72-5.66) (0.57-4.62) (0.52-5.47)
Ever injected illegal/non-medical drugs (ref. No) 2.48* 2.41* 2.65*
(1.05-5.84) (1.02-5.73) (1.08-6.49)
Ever used a needle or syringe previously used
by someone else (ref. No/Non-IDU)
2.50*
(1.35-4.63)
Used needles or syringes previously used by someone
else in the past one month (ref. Never/non-IDU)
2.60*
(1.40-4.81)
Used needles or syringes previously used by someone




Used needles or syringes previously used by someone




Ever had sexual intercourse (ref. No) 2.52 2.72 2.57
(0.40-15.96) (0.43-17.20) (0.41-16.26)
Had sexual intercourse in the last 12 months
(ref. No/Never had sex)
3.77*
(1.19-11.97)
Had sexual intercourse with regular partner in the last
12 months (ref. No/Never had sex)
1.24
(0.57-2.70)
Had sexual intercourse with commercial partner in the
last 12 months (ref. No/Never had sex)
2.20*
(1.09-4.48)
Had sexual intercourse with non-regular non-commercial
partner in the last 12 months (ref. No/Never had sex)
2.49*
(1.25-4.95)






Frequency of condom use in the last
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Table 3 Multivariate association of behavioural factors with HIV infection among female drug users in the Kathmandu
Valley, Nepal (Continued)
Frequency of condom use in the last 12 months





IDUs, injecting drug users.
aref. Never had sex/No sex with this type of sexual partner in the last 12 months.
*p value <0.05.
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to HIV infection in Nepal.
Consistent with previous studies, injection behaviour
showed a strong association with HIV infection in this
population. This association could be causal because the
sharing of injection instruments was associated strongly
with HIV infection and in a dose-dependent manner. A
study in Montreal among active drug users found that
increasing injection frequency is highly correlated with
HIV transmission, as it may reduce the chances of sterile
injecting equipment being used each time [32]. Also,
where group injecting is common, women may be the
last to use the needles/syringes [33]; this may have
strong implications with regard to the spread of HIV.
Unprotected sexual behaviour was also of great risk in
this study. Risk significantly increased for sex with com-
mercial or casual sex partners. The association of HIV
infection and sex with commercial partners was not dose-
dependent, where the people who reported more condom
use were more likely to be HIV positive. The reason for
this association could be multiple. It may be that partici-
pants who were involved in commercial sex and knew
their HIV infection before the study might have provided
socially desirable answers to our interview, or they were
really using condoms to either prevent HIV transmission
to their clients or as self-protection from re-infection. A
recent study by UNODC among female drug users in
Nepal has reported nearly 90% of condom use in last sex
act with commercial sex partners [34]. In addition, pre-
vious studies among drug users have found safer sex prac-
tices strongly associated with HIV infection. A study in
the United States found that self-reporting of being HIV-
infected was the strongest factor associated with con-
sistent condom use in the past 6 months [35]. Another
study in Puerto Rico found that HIV-positive drug users
were nearly five times more likely to use condoms during
vaginal sex [36]. In contrast, HIV infection risk of the sex
with casual partners was dose-dependent on condom use,
where the people who have less condom use are more
likely to be HIV positive. Studies in other countries have
observed the association between sex with casual partnersand HIV infection among IDUs [37]. These women may
not have skills to negotiate for condom use, and even if
the woman is aware of her HIV status, in casual relation-
ships she may not feel responsible for preventing further
transmission of HIV to this type of partner.
Injection or sexual behaviours at high risk of HIV infec-
tion were shared by around 70% or more participants with
HIV infection and even one third to half of participants
without HIV infection in this study. This strongly suggests
that if left uncontrolled the HIV epidemic could expand in
this population and that this population could continue to
be a source of HIV infection through its networks of injec-
tion and/or behavioural practices.
It is increasingly being recognized that women who use
drugs are generally different from men who use drugs,
and thus have different needs [6,38-40]. Targeted HIV pre-
vention and treatment programmes should be urgently
developed and implemented for this population. Provision
of clean needles and syringes or methadone maintenance
therapy (MMT) will be useful for the prevention of HIV
transmission through injecting network. Several studies
have shown that drug users who used needle and syringe
exchange programs were less likely to share needles and
syringes [41,42]. Programs such as needle and syringe
exchange and MMT can achieve high coverage of IDUs in
some settings [42]. A study in Amsterdam showed the
benefits of the combined availability of needle exchange
and MMT, and argued that involvement with both ser-
vices, compared to only one, was associated with a lower
incidence of HIV infections among IDUs [43]. Addition-
ally, free STI diagnosis and treatment and condom distri-
bution will be suitable for the prevention of HIV infection
through sexual network [44]. Despite mixed evidence
from three large community-based randomized controlled
trials in sub-Saharan Africa, syndromic and mass treat-
ment of STIs may contribute to HIV infection prevention
[44]. Finally, problems of drug use and commercial/casual
sex are frequently intertwined in female drug users as they
often engage in commercial/casual sex to get drugs or
money [45,46]. An overlap of sex and drug networks
among IDUs enhances their vulnerability to HIV infection
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ners. MMT, the most widely available treatment for opiate
addiction, is of particular importance since it can prevent
infection through both injecting drug use and commercial/
casual sex for drugs at the same time. MMT has shown to
reduce both injection drug use and the risk of infection
with HIV [47,48]. Since the size of this subpopulation has
been unknown, these measures should be accompanied
with studies to estimate the size of this population.
In this study, most of the behavioural questions were
taken from the standard questions of Family Health
International [27]. In this set of questions drug use and
sexual behaviours are asked, though in part covering the
participant’s lifetime, but mostly in different time frames;
one month and one year for drug use and sexual beha-
viours, respectively. Since such a difference in time
frames could influence the predictive power of the va-
riables, we compared their predictive powers and found
that predictive powers were largely independent of time
frame for both types of behaviours, suggesting that once
initiated, the same behavioural pattern will be main-
tained over a long period of time in this population.
Older age and having education remained as strong
predictors of HIV infection even in the presence of all
behavioural variables that could affect HIV infection.
Since HIV infection other than through injecting drug
use and sexual intercourse is unlikely in this population,
this may suggest the uncertainty of behavioural variables
or that the behavioural variables we used could reflect
the risk for HIV infection only partially. The uncertainty
of information could come from self-reported nature of
the information which could be affected by recall bias,
the psychotic effect of drugs or by socially desirable
answers to the sensitive and/or illegal behaviours.
One of the limitations of this study is the sampling
procedure because it was not random; the participants
may not be a true representative to the female drug user
population in the study region. Participants were re-
cruited through a snowballing process. Though efforts
were made to recruit the initial respondents in many
locations and opportunities to ensure variability, our
sampling procedure could still introduce the bias into
the participants in a way that people who have larger
social connections and have similar characteristics to ini-
tial respondents are overrepresented. To get an unbiased
prevalence of HIV infection and risky behaviours, more
sophisticated sampling methods, such as respondent
driven sampling [49-51] should be considered. Finally,
cross-sectional design of this study limits the causal in-
ference in association detected in this study.
Conclusions
HIV was highly prevalent among female drug users in
Kathmandu Valley, with its risk being strongly associatednot only with unsafe injection practice but also with
unsafe sexual behaviours. Awareness raising programmes
and preventive measures such as condom distribution,
needle or syringe exchange or methadone maintenance
therapy should be urgently introduced in this neglected
subpopulation.
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